ADIPOQ and Miyoshi myopathy: Adiponectin, therefore, has the potential to serve as a biomarker or therapeutic molecule in MM and a preclinical model in which acetyl‐coenzyme A carboxylase, an enzyme that maintains hypoadiponectinaemia, is inhibited has been described.99